The Life Sciences Report Examines How Sunesis

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
254
The Life Sciences Report Examines How Sunesis Pharmaceuticals Shifts Focus to Leukemia Drug

SAN FRANCISCO, CA --(Marketwired - May 19, 2017) - In light of a decision to pull its application for approval of vosaroxin in the European Union, Sunesis Pharmaceuticals Inc. ( NASDAQ : SNSS ) has designated its BTK inhibitor program targeting chronic lymphocytic leukemia as its new lead program.

Included in this article is: Sunesis Pharmaceuticals Inc.

In a May 1 research report, Wells Fargo expressed the view that SNS062, the Sunesis Pharmaceuticals Inc. drug in development for patients with chronic lymphocytic leukemia (CLL) that is resistant to Imbruvica (ibrutinib), is "a greater value driver for the stock."

The report notes that company resources directed toward gaining approval from the European Medicines Agency for vosaroxin, which targets acute myeloid leukemia, will now be directed toward a clinical trial for SNS062.

"We see significant upside potential on novel BTK inhibitor SNS062 in the large IMBRUVICA resistance market and with potential validation by YE17," the Wells Fargo report concludes.

In a May 10 report, Edison Investment Research states that Sunesis "will be initiating a Phase Ib/II clinical trial in Q217" for SNS062. The study is expected to read out in September 2018.

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

DISCLOSURE:

The following companies mentioned are sponsors of Streetwise Reports: Sunesis Pharmaceuticals Inc. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Please see the end of the article for the complete disclosures: Sunesis Pharmaceuticals Shifts Focus to Leukemia Drug

Contact Information: Carrie Beal Amaro Associate Publisher Email contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LV Petroleum Expands Footprint with Key Acquisitions

Updated Category News Views 0

LV Petroleum's Bold Moves in July Ever seen a company expand across four states in a blink? LV Petroleum's been hustling like a player with a fresh hand of aces. They shut July down with restaurant openings and a fancy new travel center under their belt in states as spread out as Arizona, Texas, Nevada, and Ohio. Now that's a wide net they're casting, all in the name of...

Continue Reading
ECRI Welcomes Safety Expert Meshkati to Its Board

Updated Category News Views 1

The Safety Maverick Steps into Healthcare They've gone and done it—appointed a rockstar of systems safety to ECRI's Board of Trustees. Professor Najmedin Meshkati, who's practically been around every major industrial accident of the past few decades, is about to shake things up. Imagine the guy who's dissected calamities like the BP Texas City Refinery explosion and the...

Continue Reading
PGI's Award-Winning Febreze Cabin Air Filters Shines Again

Updated Category News Views 9

A Breath of Fresh Air for the Auto Aftermarket How often do you even think about the quality of air inside your vehicle? If you're like most folks, it's not often. But Premium Guard Inc. (PGI) has been busy changing that narrative. Their Febreze Cabin Air Filters just snagged the 2026 MOTOR Top 20 Awards, proving that they're not just a pretty face in the automotive...

Continue Reading
Taiwan's Machine Emerges as Heavy-Tonnage Game Changer

Updated Category News Views 2

Every once in a while, the machinery scene gets rocked by something that genuinely raises eyebrows, and it seems Chuan Lih Fa Machinery Works Co., Ltd. (CLF) has just delivered one of those moments. This isn't just any old injection molding machine—it's Taiwan's very first 5000-ton giant, crafted with robust precision and dispatched straight to a major U.S. logistics...

Continue Reading
Courtesy Auto Group Expands with Tucson Dealerships Buy

Updated Category News Views 4

Moving Pieces in the Automotive Puzzle Here's one for the books, folks. Automotive dealership chessboard gets another shuffle. Scott Gruwell, the big wheel behind Courtesy Automotive Group, has snatched up Watson Chevrolet and Infiniti of Tucson. Just one more notch in someone's power belt—operations now rolling under new banners as Courtesy Chevrolet and Courtesy...

Continue Reading
Ribbonwire Ranch Hits Sheetz Milestone with Campaign

Updated Category News Views 3

Where Beef Snacks Meet Road Tales Just a year ago, Ribbonwire Ranch, a small Texas-based beef snack producer, made its debut at Sheetz stores. Now, they're not just another brand on the shelf; they're weaving tales from the road with their latest venture, the "Dashboard Diaries" campaign. If you're wondering how a beef snack producer finds itself in an eight-week...

Continue Reading
CAPR Faces Lawsuit and FDA Delay: Investor Alert

Updated Category News Views 0

Trouble Brewin' for Capricor Investors Buckle up, folks. Capricor Therapeutics (NASDAQ: CAPR) is caught in a storm, facing not just the lengthy arm of law with a securities class action, but also a seemingly endless wait with the FDA's decision on their lead product. We're talking serious implications for anyone with skin in the game. The FDA's Delayed Blessing So the...

Continue Reading
Regeneron: Investors Face Class Action Over Study Flaws

Updated Category News Views 0

Regeneron Investors Grit Teeth Amid Lawsuit Drama The gloves are off in the pharmaceutical battleground, folks. Investors who thought they were riding the big wave with Regeneron Pharmaceuticals (NASDAQ: REGN) are now staring down the barrel of a class action lawsuit. It seems the company’s been caught in a storm of legal action following allegations of misleading...

Continue Reading
Max Stock Expands with Strategic Logistics Center

Updated Category News Views 1

Expansion in Full Swing In a move that might get tongues wagging in the boardrooms across Israel, Max Stock Limited (TASE: MAXO) just signed a hefty lease for a logistics center in Ofakim. This isn't just a modest expansion—it's a jaw-dropper at about 45,000 square meters. We're talking about a major upgrade that'll beef up their logistical backbone as they continue...

Continue Reading
Beyoncé Drops Remastered 'B'DAY'; Celebrates Legacy

Updated Category News Views 0

Every so often, an artist comes around who's not just making music but shifting the very landscape of their genre. Beyoncé isn't just marking her birthday today; she's reminding the world of a career-defining moment with the release of her remastered deluxe version of 'B'DAY'. This isn't just a stroll down memory lane; it's a full-blown revival of an era that reshaped...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding the Options Market Trends for Nano Nuclear Energy

Updated Category News Views 109

Exploring Current Trends in the Options Market for Nano Nuclear Energy Recent movements among financial giants suggest a notable bearish sentiment surrounding Nano Nuclear Energy. Analyzing the options history for Nano Nuclear Energy (NNE), we have identified 12 unusual trades that indicate evolving market perspectives. In our detailed assessment, we discovered that...

Continue Reading
NeoImmuneTech Unveils Breakthrough Results for CAR-T Therapy

Updated Category News Views 186

Promising Developments in CAR-T Therapy with NT-I7 NeoImmuneTech, Inc. has achieved significant advancements in enhancing CAR-T cell therapies, which are innovative treatments designed to combat cancer. Recent interim results from the Phase 1b clinical trial demonstrate the potential benefits of combining NT-I7 (efineptakin alfa) with CAR-T therapy, highlighting its...

Continue Reading
Owkin Teams Up with AstraZeneca to Transform Breast Cancer Testing

Updated Category News Views 156

Owkin made headlines back in 2024 when it teamed up with AstraZeneca, looking to revolutionize breast cancer diagnostics by developing an advanced tool for pre-screening gBRCA mutations. Traders were quick to pick up on this collaboration, given the critical nature of BRCA testing and its potential market impact. But let’s peel back the layers on this deal. Partnership...

Continue Reading
Medical Express Ambulance Faces Data Breach Investigation

Updated Category News Views 342

Understanding the Data Breach Investigation Edelson Lechtzin LLP, a prominent class action law firm, is currently looking into data privacy concerns affecting customers of Medical Express Ambulance, Inc. (MedEx). MedEx has reported potential unauthorized access to its network, raising significant alarm regarding the safety of customer data. Medical Express Ambulance, Inc....

Continue Reading
Discover the 2026 Best Wellness Employer Survey Insights

Updated Category News Views 117

Wellness Workdays Unveils the 2026 Best Wellness Employer Survey In a significant move towards enhancing employee health and wellness, Wellness Workdays has launched the 2026 Best Wellness Employer survey. This initiative invites organizations to showcase their dedication to improving workplace well-being through sustainable practices and measurable results. Collaboration...

Continue Reading